Aquestive Therapeutics (AQST) reported Q4 net loss Wednesday of $0.19 per share, widening from a loss of $0.12 a year earlier.
Two analysts polled by FactSet expected a loss of $0.14.
Revenue for the quarter ended Dec. 31 was $11.9 million, down from $13.2 million a year earlier.
Analysts surveyed by FactSet expected $13.1 million.
For the full-year 2025, the company said it expects total revenue in the range of $47 million to $56 million. Analysts polled by FactSet expect $53 million.
Aquestive's stock was down 4.3% in after-hours activity Wednesday.
Price: 2.67, Change: -0.12, Percent Change: -4.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。